Open an account

Exelixis

EXEL · NASDAQ

$64.39+$1.71 (+2.73%)TodayMarket closed ·
Prev close $62.68

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Employees
1,077
Headquarters
Alameda, California
Listed
Apr 11, 2000
Sector
Health Care
Industry
Biotechnology
Website
exelixis.com

EXEL key statistics

Market cap
15.95B
Price-earnings ratio
19.71
Dividend yield
—
Average volume
2.31M
Volume
2.14M
Open price
$63.01
High today
$64.42
Low today
$62.85
52 Week high
$63.39
52 Week low
$33.76

Exelixis (EXEL) at a glance

As of Oct 20, 2026, Exelixis (EXEL) shares are priced at $64.39, giving the company a market cap of 15.95B and a price-to-earnings ratio of 19.71.

Today the stock has traded between $62.85 and $64.42. The current price is 2.5% above the day's low and 0.0% below its high.

Volume so far is 2.14M shares, in line with the average of 2.31M shares a day.

Over the past year Exelixis has ranged from $33.76 to $63.39, and now sits 103% of the way up that range.

Exelixis met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.82 per share against an estimate of $0.8017.

The average analyst price target is $54.97, 14.6% below the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

29%of 14 analyst ratings say Buy
  • Buy28.6%
  • Hold71.4%
  • Sell0.0%
Price target · 18 analystsAvg $54.97
Low
$41.41
Now
$64.39
High
$69.30

EXEL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 14.5% on average.

  1. Q3 FY24: reported $0.40 per share against an estimate of $0.3528
  2. Q4 FY24: reported $0.48 per share against an estimate of $0.4338
  3. Q1 FY25: reported $0.55 per share against an estimate of $0.3691
  4. Q2 FY25: reported $0.65 per share against an estimate of $0.5702
  5. Q3 FY25: reported $0.69 per share against an estimate of $0.6314
  6. Q4 FY25: reported $0.88 per share against an estimate of $0.8221
  7. Q1 FY26: reported $0.79 per share against an estimate of $0.7177
  8. Q2 FY26: reported $0.82 per share against an estimate of $0.8017

EXEL news

  • Press releaseBusiness Wire

    Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

  • Press releasePRNewswire

    Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

  • Vandana Singh

    Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

  • Press releaseBusiness Wire

    Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

  • Press releaseBusiness Wire

    Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

  • Press releasePRNewswire

    Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

Similar companies

Companies in the same industry as Exelixis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.